Clinical Trials Browser

Phase 1/2 × mogamulizumab × Clear all

NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase 1/2 Terminated

8 enrolled 8 charts

Mycosis Fungoides, Sezary Syndrome

NCT04676087 2024-08-13

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Phase 1/2 Terminated

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00888927 2024-04-25

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Phase 1/2 Completed

42 enrolled 13 charts

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02705105 2024-04-25

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

114 enrolled 19 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 1/2 Completed

8 enrolled 10 charts

Lymphoma, Large B-Cell, Diffuse

NCT02281409 2021-04-23

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Phase 1/2 Completed

17 enrolled 13 charts

Other solid neoplasm

Advanced Solid Tumors